These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1620660)

  • 21. CCK antagonists and CCK-monoamine interactions in the control of satiety.
    Cooper SJ; Dourish CT; Clifton PG
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):291S-295S. PubMed ID: 1728842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: synergism with pharmacological levels of melatonin.
    González-Puga C; García-Navarro A; Escames G; León J; López-Cantarero M; Ros E; Acuña-Castroviejo D
    J Pineal Res; 2005 Oct; 39(3):243-50. PubMed ID: 16150104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Centrally administered cholecystokinin suppresses feeding through a peripheral-type receptor mechanism.
    Crawley JN; Fiske SM; Durieux C; Derrien M; Roques BP
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1076-80. PubMed ID: 2046021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abdominal vagal mediation of the satiety effects of exogenous and endogenous cholecystokinin in rats.
    Reidelberger RD
    Am J Physiol; 1992 Dec; 263(6 Pt 2):R1354-8. PubMed ID: 1481948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of BIM-18216, a novel cholecystokinin receptor antagonist, on food intake reduction induced by cholecystokinin.
    Laferrere B; Nguyen M; Bonhomme G; Legall A; Basdevant A; Guy-Grand B
    Behav Neurosci; 1991 Oct; 105(5):707-11. PubMed ID: 1815620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
    Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I
    Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the novel cholecystokinin receptor antagonist CR-1392 on cholecystokinin-induced antroduodenal and pyloric motor activity in vivo.
    Allescher HD; Daniel EE; Fox JE; Kostolanska F; Rovati LA
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1134-41. PubMed ID: 2600808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proglumide has access to brain and antagonizes the central satiety effect of cholecystokinin octapeptide in the dog.
    Inui A; Inoue T; Sakatani N; Oya M; Morioka H; Baba S
    Brain Res; 1987 Aug; 417(2):355-9. PubMed ID: 3651819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
    van der Bent A; Blommaert AG; Melman CT; IJzerman AP; van Wijngaarden I; Soudijn W
    J Med Chem; 1992 Mar; 35(6):1042-9. PubMed ID: 1552499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholecystokinin contracts isolated human and monkey iris sphincters; a study with CCK receptor antagonists.
    Almegård B; Stjernschantz J; Bill A
    Eur J Pharmacol; 1992 Feb; 211(2):183-7. PubMed ID: 1612109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pylorectomy reduces the satiety action of cholecystokinin.
    Moran TH; Shnayder L; Hostetler AM; McHugh PR
    Am J Physiol; 1988 Dec; 255(6 Pt 2):R1059-63. PubMed ID: 3202221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the receptors and mechanisms involved in the cardiovascular actions of sCCK-8 in the pithed rat.
    Gaw AJ; Hills DM; Spraggs CF
    Br J Pharmacol; 1995 Jun; 115(4):660-4. PubMed ID: 7582487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effects of CCK receptor antagonists on rat pancreatic secretion in vivo.
    Niederau M; Niederau C; Strohmeyer G; Grendell JH
    Am J Physiol; 1989 Jan; 256(1 Pt 1):G150-7. PubMed ID: 2463767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholecystokinin stimulates neuronal receptors to produce contraction of the canine colon.
    Barone FC; Bondinell WE; Labosh TJ; White RF; Ormsbee HS
    Life Sci; 1989; 44(8):533-42. PubMed ID: 2927258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholecystokinin-induced satiety is mediated through interdependent cooperation of CCK-A and 5-HT3 receptors.
    Hayes MR; Savastano DM; Covasa M
    Physiol Behav; 2004 Sep; 82(4):663-9. PubMed ID: 15327914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral cholecystokinin type A receptors mediate oxytocin secretion in vivo.
    Miller TR; Bianchi BR; Witte DG; Lin CW
    Regul Pept; 1993 Jan; 43(1-2):107-12. PubMed ID: 8426907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural features of various proglumide-related cholecystokinin receptor antagonists.
    Jensen RT; Zhou ZC; Murphy RB; Jones SW; Setnikar I; Rovati LA; Gardner JD
    Am J Physiol; 1986 Dec; 251(6 Pt 1):G839-46. PubMed ID: 2431626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of CCK-A receptors induces elevation of plasma corticosterone in rats.
    Katsuura G; Ibii N; Matsushita A
    Peptides; 1992; 13(1):203-5. PubMed ID: 1620654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor.
    Yule DI; Williams JA
    Peptides; 1994; 15(6):1045-51. PubMed ID: 7527529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of proglumide on cholecystokinin-, bombesin-, and glucagon-induced satiety in the rat.
    Collins S; Walker D; Forsyth P; Belbeck L
    Life Sci; 1983 May; 32(19):2223-9. PubMed ID: 6843294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.